Oxeglitazar

Drug Profile

Oxeglitazar

Alternative Names: EMD 336340; LM 4156

Latest Information Update: 07 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sante
  • Class Antihyperglycaemics; Antihyperlipidaemics; Benzoxepins; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Gout; Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 13 Dec 2005 Phase-I clinical trials in Gout in France (PO)
  • 13 Dec 2005 Data presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2005) have been added to the Rheumatic disease pharmacodynamics section
  • 29 Aug 2003 Data presented at the 18th Congress of the International Diabetes Federation (IDF-2003) have been added to the Diabetes pharmacodynamics , pharmacokinetics and drug interactions sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top